- Home
- CMMB vs GIGM Comparison
CMMB vs GIGM Comparison
Compare CMMB & GIGM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMMB | GIGM |
|---|---|---|
| Founded | 2004 | 1998 |
| Country | Israel | Taiwan |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.1M | 17.2M |
| IPO Year | 2023 | 2002 |
Fundamental Metrics
Financial Performance| Metric | CMMB | GIGM |
|---|---|---|
| Price | $1.86 | $1.56 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $25.00 | N/A |
| AVG Volume (30 Days) | ★ 69.1K | 6.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.67 | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $48.75 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.87 | $1.38 |
| 52 Week High | $3.86 | $1.89 |
Technical Indicators
Market Signals| Indicator | CMMB | GIGM |
|---|---|---|
| Relative Strength Index (RSI) | 53.82 | 45.99 |
| Support Level | $1.57 | $1.42 |
| Resistance Level | $2.80 | $1.58 |
| Average True Range (ATR) | 0.19 | 0.04 |
| MACD | 0.03 | -0.00 |
| Stochastic Oscillator | 62.51 | 72.22 |
Price Performance
Historical ComparisonAbout CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101, treating rare fibrotic conditions.
About GIGM GigaMedia Limited
GigaMedia Ltd is a diversified provider of digital entertainment services. Its only segment and principal business is digital entertainment service business, which operates a portfolio of digital entertainment products, targeting digital entertainment service users across Asia. It operates digital entertainment business in Taiwan, Hong Kong and Macau through FunTown.